Omeros swings to Q4 profit on sale of zaltenibart

Reuters04-01

Omeros swings to Q4 profit on sale of zaltenibart

Overview

Biotechnology company reported Q4 net income of $86.5 mln, up from a year-ago loss
Q4 results include $237.6 mln gain from zaltenibart sale to Novo Nordisk

Outlook

Company expects EMA decision on YARTEMLEA marketing authorization in mid-2026
Omeros targets positive cash flow in 2027

Result Drivers

ZALTENIBART SALE - Q4 results driven by $237.6 mln gain from sale of zaltenibart to Novo Nordisk
OPERATING EXPENSES - Lower operating expenses due to reduced manufacturing and clinical trial costs and spending cuts ahead of YARTEMLEA launch

Company press release: ID:nBwb2bs4la

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		$1.22
Q4 Net Income		$86.5 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Omeros Corp is $40.00, about 307.7% above its March 30 closing price of $9.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624374485?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624374485","market":"fut","top_or_hot":-1,"title":"Omeros swings to Q4 profit on sale of zaltenibart","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Omeros swings to Q4 profit on sale of zaltenibart </title></head><body><p><span>Overview</span></p><ul><li><p>Biotechnology company reported Q4 net income of $86.5 mln, up from a year-ago loss</p></li><li><p>Q4 results include $237.6 mln gain from zaltenibart sale to <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a></p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects EMA decision on YARTEMLEA marketing authorization in mid-2026</p></li><li><p>Omeros targets positive cash flow in 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZALTENIBART SALE - Q4 results driven by $237.6 mln gain from sale of zaltenibart to Novo Nordisk</p></li><li><p>OPERATING EXPENSES - Lower operating expenses due to reduced manufacturing and clinical trial costs and spending cuts ahead of YARTEMLEA launch</p></li></ul><p>Company press release: <span>ID:nBwb2bs4la</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$1.22</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$86.5 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Omeros Corp is $40.00, about 307.7% above its March 30 closing price of $9.81</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros swings to Q4 profit on sale of zaltenibart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros swings to Q4 profit on sale of zaltenibart\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 04:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Omeros swings to Q4 profit on sale of zaltenibart </title></head><body><p><span>Overview</span></p><ul><li><p>Biotechnology company reported Q4 net income of $86.5 mln, up from a year-ago loss</p></li><li><p>Q4 results include $237.6 mln gain from zaltenibart sale to <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a></p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects EMA decision on YARTEMLEA marketing authorization in mid-2026</p></li><li><p>Omeros targets positive cash flow in 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZALTENIBART SALE - Q4 results driven by $237.6 mln gain from sale of zaltenibart to Novo Nordisk</p></li><li><p>OPERATING EXPENSES - Lower operating expenses due to reduced manufacturing and clinical trial costs and spending cuts ahead of YARTEMLEA launch</p></li></ul><p>Company press release: <span>ID:nBwb2bs4la</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$1.22</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$86.5 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Omeros Corp is $40.00, about 307.7% above its March 30 closing price of $9.81</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J170:1","article_id":"2624374485","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624374485","pubTimestamp":1774987955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Omeros swings to Q4 profit on sale of zaltenibartOverviewBiotechnology company reported Q4 net income of $86.5 mln, up from a year-ago lossQ4 results include $237.6 mln gain from zaltenibart sale to N","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OMER":"奥麦罗制药"},"translate_title":"Omeros通过出售zaltenibart实现第四季度盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":0.9},"content_text":"Omeros swings to Q4 profit on sale of zaltenibart OverviewBiotechnology company reported Q4 net income of $86.5 mln, up from a year-ago lossQ4 results include $237.6 mln gain from zaltenibart sale to Novo NordiskOutlookCompany expects EMA decision on YARTEMLEA marketing authorization in mid-2026Omeros targets positive cash flow in 2027Result DriversZALTENIBART SALE - Q4 results driven by $237.6 mln gain from sale of zaltenibart to Novo NordiskOPERATING EXPENSES - Lower operating expenses due to reduced manufacturing and clinical trial costs and spending cuts ahead of YARTEMLEA launchCompany press release: ID:nBwb2bs4laKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS$1.22Q4 Net Income$86.5 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Omeros Corp is $40.00, about 307.7% above its March 30 closing price of $9.81For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624374485","isCrawlerRequest":true}